REGEN-COV is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Casirivimab; Imdevimab.
Product ID | 61755-039_1b115152-c792-4dbd-aede-52dc7fdf8436 |
NDC | 61755-039 |
Product Type | Human Prescription Drug |
Proprietary Name | REGEN-COV |
Generic Name | Casirivimab And Imdevimab |
Dosage Form | Injection, Solution, Concentrate |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2021-06-03 |
Marketing Category | UNAPPROVED DRUG OTHER / |
Labeler Name | Regeneron Pharmaceuticals, Inc. |
Substance Name | CASIRIVIMAB; IMDEVIMAB |
Active Ingredient Strength | 600 mg/10mL; mg/10mL |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2021-06-03 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
61755-035 | REGEN-COV | casirivimab and imdevimab |
61755-036 | REGEN-COV | casirivimab and imdevimab |
61755-037 | REGEN-COV | casirivimab and imdevimab |
61755-038 | REGEN-COV | casirivimab and imdevimab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
REGEN-COV 90284296 not registered Live/Pending |
Regeneron Pharmaceuticals, Inc. 2020-10-28 |